Prosight Management, LP holds a focused book of 46 stocks worth $609.8M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Alkermes PLC and trimmed Adc Therapeutics Sa. Their largest long position is Nektar Therapeutics at 9% of the equity book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Prosight Management, LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 54 / 46 | $38.8B |
| UBS Group AG | 54 / 46 | $4.3B |
| MORGAN STANLEY | 53 / 46 | $8.4B |
| BNP PARIBAS FINANCIAL MARKETS | 53 / 46 | $1.0B |
| GEODE CAPITAL MANAGEMENT, LLC | 52 / 46 | $9.4B |
| NORTHERN TRUST CORP | 52 / 46 | $4.0B |
| BARCLAYS PLC | 52 / 46 | $1.4B |
| Tower Research Capital LLC (TRC) | 52 / 46 | $26.7M |
Ranked by the share of each fund's own book sitting in the names it shares with Prosight Management, LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Nektar Therapeutics COM NEW | $52.9M | 735.0K | 8.7% | ▲+33% Added · +180K sh | |
| 2 | Boston Scientific Corp COM | $49.9M | 795.5K | 8.2% | ▲+279% Added · +586K sh | |
| 3 | Janux Therapeutics Inc COM | $49.3M | 3.55M | 8.1% | ▲+48% Added · +1.2M sh | |
| 4 | Procept Biorobotics Corp COM | $48.6M | 1.95M | 8.0% | ▲+41% Added · +565K sh | |
| 5 | Galapagos NV SPON ADR | $46.5M | 1.55M | 7.6% | ▲+44% Added · +476K sh | |
| 6 | Genedx Holdings Corp COM CL A | $33.6M | 523.5K | 5.5% | ▲+852% Added · +468K sh | |
| 7 | Shattuck Labs Inc COM | $32.2M | 5.00M | 5.3% | ▲+110% Added · +2.6M sh | |
| 8 | Adc Therapeutics Sa SHS | $31.1M | 8.30M | 5.1% | ▼−2.1% Reduced · −177K sh | |
| 9 | Kura Oncology Inc COM | $27.3M | 3.36M | 4.5% | ▲+33% Added · +827K sh | |
| 10 | Alnylam Pharmaceuticals Inc COM | $25.1M | 76.0K | 4.1% | ▲+344% Added · +59K sh | |
| 11 | Meiragtx Hldgs PLC COM | $22.8M | 2.63M | 3.7% | ▼−18% Reduced · −580K sh | |
| 12 | Alkermes PLC SHS | $18.2M | 513.6K | 3.0% | ▲New New position | |
| 13 | Syndax Pharmaceuticals Inc COM | $18.0M | 770.0K | 2.9% | ▲+16% Added · +105K sh | |
| 14 | Veeva Sys Inc CL A COM | $15.2M | 86.5K | 2.5% | ▼−4.0% Reduced · −4K sh | |
| 15 | Zymeworks Inc COM | $13.5M | 539.0K | 2.2% | ▲+1.6% Added · +9K sh | |
| 16 | Crinetics Pharmaceuticals In COM | $12.7M | 350.0K | 2.1% | ▲+33% Added · +87K sh | |
| 17 | Abivax Sa SPONSORED ADS | $11.7M | 105.0K | 1.9% | ▲+518% Added · +88K sh | |
| 18 | Concentra Group Holdings Par COMMON STOCK | $10.8M | 505.8K | 1.8% | ▼−43% Reduced · −385K sh | |
| 19 | Terns Pharmaceuticals Inc COM | $10.7M | 202.3K | 1.7% | ▲+113% Added · +107K sh | |
| 20 | Phreesia Inc COM | $9.2M | 1.10M | 1.5% | ▲+13% Added · +123K sh | |
| 21 | Onkure Therapeutics Inc COM CL A | $8.9M | 2.15M | 1.5% | ▲+164% Added · +1.3M sh | |
| 22 | Corbus Pharmaceuticals Hldgs COM NEW | $6.5M | 697.1K | 1.1% | ▲+1.9% Added · +13K sh | |
| 23 | Schrodinger Inc COM | $5.8M | 510.6K | 1.0% | ▲New New position | |
| 24 | Emergent Biosolutions Inc COM | $5.3M | 639.1K | 0.9% | ▲New New position | |
| 25 | Roivant Sciences Ltd SHS | $5.0M | 180.0K | 0.8% | ▼−71% Reduced · −447K sh | |
| 26 | Orthopediatrics Corp COM | $4.8M | 302.4K | 0.8% | ▲+121% Added · +166K sh | |
| 27 | Immunovant Inc COM | $4.4M | 175.8K | 0.7% | ▼−28% Reduced · −68K sh | |
| 28 | Icu Med Inc COM | $3.5M | 27.4K | 0.6% | ▲New New position | |
| 29 | Tectonic Therapeutic Inc COM | $2.5M | 79.9K | 0.4% | ▼−66% Reduced · −155K sh | |
| 30 | Rocket Pharmaceuticals Inc COM | $2.4M | 683.9K | 0.4% | ▼−8.1% Reduced · −60K sh | |
| 31 | Upstream Bio Inc COM | $2.2M | 241.1K | 0.4% | ▲New New position | |
| 32 | Pliant Therapeutics Inc COM | $2.1M | 1.67M | 0.3% | ▲+7.2% Added · +112K sh | |
| 33 | Omeros Corp COM | $1.8M | 174.8K | 0.3% | ▲New New position | |
| 34 | Intuitive Surgical Inc COM NEW | $1.8M | 4.0K | 0.3% | ▲New New position | |
| 35 | An2 Therapeutics Inc COM | $1.8M | 515.8K | 0.3% | ▲New New position | |
| 36 | Adicet Bio Inc COM NEW | $1.7M | 250.2K | 0.3% | —Held | |
| 37 | Regenxbio Inc COM | $1.7M | 200.0K | 0.3% | ▲New New position | |
| 38 | Coya Therapeutics Inc COMMON STOCK | $1.7M | 420.4K | 0.3% | ▲New New position | |
| 39 | Viking Therapeutics Inc COM | $1.5M | 45.0K | 0.2% | ▲New New position | |
| 40 | Irhythm Holdings Inc COM | $1.2M | 10.0K | 0.2% | ▲New New position | |
| 41 | Trueblue Inc COM | $974K | 249.1K | 0.2% | ▼−44% Reduced · −193K sh | |
| 42 | Immuneering Corp CLASS A COM | $650K | 123.4K | 0.1% | ▲New New position | |
| 43 | Palvella Therapeutics Inc Ne COM | $623K | 5.0K | 0.1% | ▲New New position | |
| 44 | Novocure Ltd ORD SHS | $549K | 50.4K | 0.1% | ▲New New position | |
| 45 | Rein Therapeutics Inc COM NEW | $535K | 411.6K | 0.1% | ▼−7.0% Reduced · −31K sh | |
| 46 | Transmedics Group Inc COM | $497K | 5.0K | 0.1% | ▲New New position |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1617201/holdings"
Use Arkolith to show Prosight Management, LP's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.